Savings and support
for your patients

Eligible patients can pay as little as $15* per fill

Encourage your patients to sign up for a Motegrity Savings Card

With the Motegrity Savings Card, eligible patients can pay as little as $15* for each 30-day prescription fill of Motegrity. This offer is valid for up to 15 uses, or until the program expires.

*Up to $90 max benefit per 30-day prescription. See below for Terms and Conditions.

Motegrity savings card

Terms & Conditions

Eligible Commercially Insured patients may pay as little as [$15 ] and receive up to [$90 ] off their co-pay or out of pocket expenses per 30 day supply of Motegrity™ (prucalopride). Offer valid for up to [15] uses through offer expiry. A valid Prescriber ID# is required on the prescription. Offer valid for patients ages 18 and older. [Offer not valid for cash paying patients.]

Restrictions: This offer is only valid for residents of the United States, Puerto Rico and U.S. Territories. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare, or other federal or state health programs (including any state medical assistance program) or where prohibited by the health insurance provider. Cash Discount Cards and other non-insurance plans are not valid as primary under this offer. If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payor of the existence and/or value of this offer. Offer not valid for patients under 18 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. If your insurance situation changes, it is your responsibility to notify [customer service at 1-833-666-2499]. This offer is not transferable and is limited to one offer per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer. Not valid if reproduced. Void where prohibited by law. Program managed by ConnectiveRx on behalf of Takeda Pharmaceuticals U.S.A., Inc. The parties reserve the right to discontinue, rescind, revoke or amend this offer without notice at any time. This is not health insurance.

Coverage questions?
Contact Motegrity Answers

Call 1-844-447-2582 for assistance

Get answers about Motegrity, including:

  • Savings program
  • Benefits investigation
  • Prior authorization

Motegrity Answers is available Monday through Friday from 8 a.m. to 8 p.m. ET

Map icon

Formulary Coverage

Briefcase icon

Request a Rep Visit

Submit a request to speak with a Takeda representative

Submit Request
Bottle icon

Request Samples

Interested in receiving
samples of Motegrity?

Request Samples



  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for persistent worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if their depression is persistently worse, or they experience emerging suicidal thoughts or behaviors.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis


Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.